East Asian Breast Cancer Genome Atlas and Recurrence Risk Prediction

National Taiwan University

Status: Enrolling

Conditions: Breast Cancer

Treatments: Other: PAM50

Study type: Observational

Funder types: Other

Identifiers

NCT04344496

201805027RSA

Details and patient eligibility

About

This project aims to establish the cancer genome atlas and the platform of recurrence risk prediction specific for East Asian breast cancer patients. The study was planned to collect blood sample, fresh tumor tissue, and paraffin embedded tumor tissue from 2000 patients. Aims to identify unique genetic alterations in Asian tumors, to identify the susceptible genes for breast carcinogenesis in East Asia, and to establish the new platform for accurate prediction of recurrence. The investigator will explore the association of patient outcomes with the genetic alterations from the cancer atlas of East Asian breast tumors.

Enrollment: 2,000 estimated patients

Sex: All

Ages: 20+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• 1. Aged more than 20-year-old at the time of informed consent.
• 2. An unconfirmed breast tumor, or have histologically confirmed invasive breast cancer.
• 3. Have radiological or objective evidence of breast tumor size ≥1 cm.
• 4. Be able to comply with study procedures to collect the clinical medical information, blood sample, fresh tumor tissue, and 12 sections of paraffin embedded tumor tissue.
• 5. Be able to sign an informed consent.

Exclusion criteria

• 1. Have histologically confirmed ductal carcinoma in situ (DCIS).
• 2. Stage I, II or III breast cancer patients who have received neoadjuvant treatments, including chemotherapy, hormonal therapy, or targeted therapy.
• 3. Stage IV or metastatic breast cancer patients who have received chemotherapy.